Advanced Skin Cancer Diagnostic Tests Overlay Biology on Top of Pathology to Determine...

Advanced Skin Cancer Diagnostic Tests Overlay Biology on Top of Pathology to Determine Appropriate Treatment


An Empowered Patient Podcast hosted by Karen Jagoda


Derek Maetzold, President and CEO of Castle Biosciences is harnessing the power of genomics to understand the biology of skin cancer.


Castle has developed genomic tests to determine how aggressive melanoma and squamous cell carcinoma are in order to better inform dermatologist and patients about intervention decisions. With both diagnostic and prognostic tests and assist from artificial intelligence machine learning-based algorithms, calculations are made for assessing the risk of developing metastatic disease for each individual patient.


Listen to Podcast: https://empoweredpatientradio.com/advanced-skin-cancer-diagnostic-tests-overlay-biology-on-top-of-pathology-to-determine-appropriate-treatment


Transcript of Podcast: https://empoweredpatientradio.com/advanced-skin-cancer-diagnostic-tests-overlay-biology-on-top-of-pathology-to-determine-appropriate-treatment-transcript


Castle Biosciences website: https://www.castlebiosciences.com




Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC